IO Biotech Files 8-K: Material Agreement & Financial Obligation
Ticker: IOBT · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1865494
| Field | Detail |
|---|---|
| Company | Io Biotech, Inc. (IOBT) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.001, $50 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
IO Biotech inked a new deal, took on debt, and sold stock on Dec 19th. Details TBD.
AI Summary
On December 19, 2024, IO Biotech, Inc. entered into a material definitive agreement and created a direct financial obligation. The company also reported unregistered sales of equity securities and provided a Regulation FD disclosure. Specific details regarding the agreement, financial obligation, and equity sales were not provided in this filing.
Why It Matters
This filing indicates significant corporate actions, including new financial commitments and equity transactions, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, suggesting potentially significant financial and operational changes for the company.
Key Players & Entities
- IO Biotech, Inc. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by IO Biotech, Inc. on December 19, 2024?
The filing states that IO Biotech, Inc. entered into a material definitive agreement on December 19, 2024, but the specific details of this agreement are not disclosed in the provided text.
What type of direct financial obligation or off-balance sheet arrangement was created by IO Biotech, Inc.?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement by IO Biotech, Inc. on December 19, 2024, but the specifics are not detailed.
Were there any unregistered sales of equity securities by IO Biotech, Inc. reported in this filing?
Yes, the filing reports unregistered sales of equity securities by IO Biotech, Inc. as an item of information.
What is the principal executive office address for IO Biotech, Inc.?
The principal executive offices of IO Biotech, Inc. are located at Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.
What is the filing date and the period of report for this 8-K filing?
This 8-K filing was filed as of December 20, 2024, and the conformed period of report is December 19, 2024.
Filing Stats: 2,411 words · 10 min read · ~8 pages · Grade level 13 · Accepted 2024-12-20 08:10:30
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share IOBT The Nasdaq Stock Mar
- $50 million — C, which include raising an additional $50 million in cash and submission of an applicatio
Filing Documents
- d815097d8k.htm (8-K) — 43KB
- d815097dex41.htm (EX-4.1) — 221KB
- d815097dex101.htm (EX-10.1) — 657KB
- d815097dex102.htm (EX-10.2) — 283KB
- d815097dex103.htm (EX-10.3) — 37KB
- d815097dex104.htm (EX-10.4) — 325KB
- d815097dex105.htm (EX-10.5) — 79KB
- d815097dex991.htm (EX-99.1) — 12KB
- g815097dsp221.jpg (GRAPHIC) — 10KB
- 0001193125-24-282502.txt ( ) — 2063KB
- iobt-20241219.xsd (EX-101.SCH) — 3KB
- iobt-20241219_lab.xml (EX-101.LAB) — 17KB
- iobt-20241219_pre.xml (EX-101.PRE) — 11KB
- d815097d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 4.1 Form of Warrant. 10.1 Finance Contract, dated December 19, 2024, by and between the Borrower and EIB. 10.2 Guarantee Agreement, dated December 19, 2024, by and between the Company and EIB. 10.3 Side Letter, dated December 19, 2024, by and between the Borrower and EIB. 10.4 Warrant Issuance Agreement, dated December 19, 2024, by and between the Company and EIB. 10.5 Registration Rights Agreement, dated December 19, 2024, by and between the Company and EIB. 99.1 Press Release dated December 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IO Biotech, Inc. Date: December 20, 2024 By: /s/ Mai-Britt Zocca, Ph.D. Mai-Britt Zocca, Ph.D. Chief Executive Officer